A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Abstract
Aim To examine the safety and efficacy of modafinil (200 mg/day) compared to placebo in the treatment of methamphetamine dependence and to examine predictors of post-treatment outcome. Participants and design Eighty methamphetamine-dependent subjects in Sydney, Australia were allocated randomly to modafinil (200 mg/day) (n = 38) or placebo (n = 42) under double-blind conditions for 10 weeks with a further 12 weeks post-treatment follow-up. Measures Comprehensive drug use data (urine specimens and self-report) and other health and psychosocial data were collected weekly during treatment and research interviews at baseline, week 10 and week 22. Results Treatment retention and medication adherence were equivalent between groups. There were no differences in methamphetamine abstinence, craving or severity of dependence. Medication-compliant subjects tended to provide more methamphetamine-negative urine samples over the 10-week treatment period (P = 0.07). Outcomes were better for methamphetamine-dependent subjects with no other substance dependence and those who accessed counselling. There were statistically significant reductions in systolic blood pressure (P = 0.03) and weight gain (P = 0.05) in modafinil-compliant subjects compared to placebo. There were no medication-related serious adverse events. Adverse events were generally mild and consistent with known pharmacological effects. Conclusions Modafinil demonstrated promise in reducing methamphetamine use in selected methamp…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Incorporating telephone monitoring and counseling in follow-up care, in addition to usual care, can reduce recidivism for patients with cocaine use disorder who have criminal and/or legal system involvement.
“Research also shows that incorporating telephone monitoring and counseling in follow-up care-in addition to usual care-for patients with cocaine use disorder who have criminal and/or legal system involvement can reduce recidivism.228”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [228]
Cites
Analysing controlled trials with baseline and follow up measurements
Vickers, A. J., & Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7321.1123 · Cited by 2,116 · see citing works
Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide
Twisk, J. W. R. (2013) · doi:10.1017/cbo9781139342834 · Cited by 593 · see citing works
Sinha, R., Garcia, M., Paliwal, P., Kreek, M. J., & Rounsaville, B. J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.324 · Cited by 528 · see citing works
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391 · see citing works
Baker, A., Lee, N. K., Claire, M., Lewin, T. J., Grant, T., Pohlman, S., Saunders, J. B., Kay‐Lambkin, F., Constable, P., Jenner, L., et al. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01002.x · Cited by 227 · cited 1× · see citing works
“All subjects were offered a brief four-session cognitive behavioural intervention developed specifically for methamphetamine users [27].”
BackgroundMcGregor, C., Srisurapanont, M., Mitchell, A., Wickes, W., & White, J. M. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.12.003 · Cited by 82 · cited 1× · see citing works
“Modafinil does not appear to be behaviourally reinforcing, as use does not produce euphoria and there is no discontinuation effect [20,21].”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598 · see citing works
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332 · see citing works
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242 · see citing works
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194 · see citing works
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · see citing works
Tardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151 · see citing works
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105 · see citing works
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78 · see citing works
Drug addiction: from bench to bedside
Cheron, J., & Kerchove d’Exaerde, A. D. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01542-0 · Cited by 75 · see citing works
Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., Gamble, G., Hardley, P., Jensen, M., Kuoppasalmi, K., et al. (2013) · Addiction · doi:10.1111/add.12109 · Cited by 63 · see citing works
Brown, E. S., & Gabrielson, B. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.006 · Cited by 58 · see citing works
Bhatt, M., Zielinski, L., Baker-Beal, L., Bhatnagar, N., Mouravska, N., Laplante, P., Worster, A., Thabane, L., & Samaan, Z. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0370-x · Cited by 56 · see citing works
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42 · see citing works
Pérez-Mañá, C., Castells, X., Vidal, X., Casas, M., & Capellà, D. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.08.012 · Cited by 33 · see citing works
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13 · see citing works
- Authors
- Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A.
- Affiliations
- UNSW Sydney (AU)
- Sydney Hospital (AU)
- St Vincent's Hospital Sydney (AU)
- Corresponding author
- Darke, Shane
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2009-01-15
- Volume
- 104
- Issue
- 2
- Pages
- 224-233
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2109987251
- Cited by
- 159
- References
- 6
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 8 · 2022: 4 · 2021: 3 · 2020: 27 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 9 · 2015: 6 · 2014: 10 · 2013: 16 · 2012: 13
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Addiction (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- ANU Open Research (Australian National University) (submittedVersion)
- Funders
- Australian Government
- University of New South Wales
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- modafinil, methamphetamine dependence, stimulant use disorder, drug craving, treatment retention, medication adherence, predictors of treatment outcome, counseling, weight gain, blood pressure, adverse events
- MeSH terms
- Modafinil, Adult, Central Nervous System Stimulants, Australia, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Male, Middle Aged, Recurrence, Severity of Illness Index, Substance Abuse Detection, Treatment Outcome, Amphetamine-Related Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
